Compared with that in the low-risk group, PD1 and CTLA4 expression in the high-risk was significantly higher, suggesting that high-risk CRC patients have a potential response to anti-PD-1 immunotherapy (Figures 5B–D). The gene discussed is PDCD1; the disease is colorectal carcinoma.